Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia

Journal of Virological Methods

Volumn 119, Issue 2, 2004, Pages 73-78

  Mackie, Nicola ^a   Dustan, Simon ^a   McClure, Myra O ^a   Weber, Jonathan N ^a   Clarke, John R ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

HIV; Plasma; RT PCR

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; BLOOD SAMPLING; DILUTION; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; OLIGONUCLEOTIDE PROBE; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENES, POL; GENOTYPE; HIV-1; HUMANS; MUTATION; PHYLOGENY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 2442670063     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2004.02.015     Document Type: Article

References (23)

1. Aleman S., Soderbarg K., Visco-Comandini U., Sitbon G., Sonnerborg A. Drug resistance at low viraemia in HIV-1 infected patients with antiretroviral combination therapy. AIDS. 16:2002;1039-1044
2. Bart P.A., Rizzardi G.P., Tambussi G., Chave J.P., Chapuis A.G., Graziosi C., Corpataux J.M., Halkic N., Meuwly J.Y., Munoz M., Meylan P., Spreen W., McDade H., Yerly S., Perrin L., Lazzarin A., Pantaleo G. Immunological and virological responses in HIV-1 infected adults at early stage of established infection treated with highly active antireroviral therapy. AIDS. 14:2000;1887-1897
3. Baxter J.D., Mayers D.L., Wentworth D.N., Neaton J.D., Hoover M.L., Winters M.A., Mannheimer S.B., Thompson M.A., Abrams D.I., Brizz B.J., Ioannidis J.P., Merigan T.C. A randomised study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 study team for the Terry Bairn community programs for Clinical research on AIDS. AIDS. 14:2000;F83-F93
4. Beddows S., Galpin S., Kazmi S.H., Ashraf A., Johargy A., Frater A.J., White N., Braganza R., Clarke J., McClure M., Weber J. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subgroups. J. Med. Virol. 70:2003;337-342
5. Carpenter, C.C., Cooper, D.A., Fischl, M.A., Gatell, J.M., Gazzard, B.G., Hammer, S.M., Hirsch, M.S., Jacobsen, D.M., Katzenstein, D.A., Montaner, J.S., Richman, D.D., Saag, M.S., Schechter, M., Schooley, R.T., Thompson, M.A., Vella, S., Yeni, P.G., Volberding, P.A., 2000. Antiviral therapy in adults: updated recommendations of the International AIDS society-USA panel. JAMA 283, 381-390.
6. Cingolani A., Antinori A., Rizzo M.G., Murri R., Ammassari A., Baldini F., Di Gambenedetto S., Cauda R., DeLuca A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy. A randomised study (ARGENTA). AIDS. 16:2002;369-379
7. Clarke J.R., Galpin S., Braganza R., Ashraf A., Russell R., Churchill D.R., Weber J.N., McClure M.O. Comparative quantification of diverse serotypes of HIV-1 in plasma from a diverse population of patients. J. Med. Virol. 62:2000;445-449
8. Clewley J.P., Arnold C., Barlow K.L., Grant P.R., Parry J.V. Diverse HIV-1 genetic subtypes in UK. Lancet. 347:1996;1487
9. Deeks S.G. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. JAMA. 286:2001;224-226
10. Durant J., Clevenborough P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C.A., Schipiro J.M., Dellamonica P. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomised control trial. Lancet. 353:1999;2195-2199
11. Elbeik T., Hoo B.S., Campodonico M.E., Dileanis J., Fay F.F., Bortolozzi R.L., Benetti M.S., Fay O.H., Marlowe N., Petrauskene O., Chernoff D., Smith L., Ng V.L. In vivo emergence of drug-resistant mutations at less than 50 copies/ml that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type 1 infected patients on highly active antiretroviral therapy. J. Hum. Virol. 4:2001;317-328
12. Erali M., Page S., Reimer L.G., Hillyard D.R. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J. Clin. Microbiol. 39:2001;2157-2165
13. Fontaine E., Riva C., Peeters M., Schmit J.C., Delaporte E., Van Laethem K., Van Vaerenbergh K., Snoek J., Van Wijngaerden E., DeClercq E., Van Ranst M., Vandamme A.M. Evaluation of two commercial kits for the detection og genotypic drug resistance on a panel of HIV-1 type 1 subtypes A through J. J. Acquir. Immune Defic. Syndr. 28:2001;254-258
14. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., Hammer S.M., Johnson V.A., Kuritzkes D.R., Loveday C., Mellors J.W., Clotet B., Conway B., Demeter L.M., Vella S., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA. 283:2000;2417-2426
15. Jagodinski L.L., Cooley J.D., Weber M., Michael N.L. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than subtype B. J. Clin. Microbiol. 41:2003;998-1003
16. Mracna M., Becker-Pergola G., Dileanis J., Guay L.A., Cunningham S., Jackson J.B., Eshleman S.H. Performance of applied biosystems viroseq HIV-1 genotyping system for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J. Clin. Microbiol. 39:2001;4323-4327
17. Pozniak A., Gazzard B., Anderson J., Babiker A., Churchill D., Collins S., Fisher M., Johnson M., Koo S., Leen C., Loveday C., Moyle G., Nelson M., Peters B., Phillips A., Pillay D., Wilkins E., Williams I., Youle M. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 4(Suppl. 1):2003;1-41
18. Price D.A., Scullard G., Oxenius A., Braganza R., Beddows S.A., Kazmi S., Clarke J.R., Johnson G.E., Weber J.N., Phillips R.E. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific immunity. J. Virol. 77:2003;6041-6049
19. Schuurman R., Brambilla D., deGroot T., Huang D., Land S., Bremer J., Benders I., Boucher C.A. Underestimation of HIV type 1 drug resistance mutations. Results from ENVA-2 genotyping proficiency program. AIDS Res. Hum. Retroviruses. 18:2002;243-248
20. Sturmer M., Berger A., Doerr H.-W. Modifications and substitutions of the RNA extraction module in the Viroseq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay. J. Med. Virol. 71:2003;475-479
21. The Euro Guidelines Group for HIV Resistance. 2001. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management. Recommendations for the European setting. AIDS 15, 309-320.
22. Tural C., Ruiz L., Holtzer C., Schapiro J., Viciana P., Gonzales J., Domingo P., Boucher C., Rey-Joly C., Clotet B. Clinical utility of HIV-1 genotyping and expert advice. The Havana trial. AIDS. 16:2002;209-218
23. Vandamme A.M., Houyez F., Banheygi D., Clotet B., DeSchrijver G., DeSmet K.A., Hall W.W., Harrigan R., Hellmann N., Hertogs K., Holtzer C., Larder B., Pillay D., Race E., Scmit J.C., Schuurman R., Schulse E., Sonnerborg A., Miller V. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow up. Antiviral Ther. 6:2001;21-39